Correction to Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study (The Lancet Gastroenterology & Hepatology (2017) 2(3) (200–210)(S2468125316301820)(10.1016/S2468-1253(16)30182-0));Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 3, 2017, Pages 200-210

  Islam, Nazrul ^a,b   Krajden, Mel ^a,b   Shoveller, Jean ^a,c   Gustafson, Paul ^a   Gilbert, Mark ^b,d   Buxton, Jane A ^a,b   Wong, Jason ^a,b   Tyndall, Mark W ^a,b   Janjua, Naveed Zafar ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d ONTARIO HIV TREATMENT NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; HEALTH SERVICE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; BRITISH COLUMBIA; COHORT ANALYSIS; COMPLICATION; COUNSELING; DRUG THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL DISEASE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; RECURRENT DISEASE; SECONDARY PREVENTION; SUBSTANCE ABUSE;

ADULT; BRITISH COLUMBIA; COHORT STUDIES; COUNSELING; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MENTAL DISORDERS; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85012165150     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30011-0     Document Type: Erratum

References (57)

1. 1 Gower, E, Estes, C, Blach, S, Razavi-Shearer, K, Razavi, H, Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:suppl 1 (2014), S45–S57.
2. 2 Armstrong, GL, Wasley, A, Simard, EP, McQuillan, GM, Kuhnert, WL, Alter, MJ, The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006), 705–714.
3. 3 Robotin, MC, Copland, J, Tallis, G, et al. Surveillance for newly acquired hepatitis C in Australia. J Gastroenterol Hepatol 19 (2004), 283–288.
4. 4 Grebely, J, Prins, M, Hellard, M, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 12 (2012), 408–414.
5. 5 Islam, N, Krajden, M, Gilbert, M, et al. Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: the BC Hepatitis Testers Cohort. J Viral Hepat, 2016, 10.1111/jvh.12650 published online Nov 25.
6. 6 Abdel-Hakeem, MS, Shoukry, NH, Protective immunity against hepatitis C: many shades of gray. Front Immunol, 5, 2014, 274.
7. 7 Osburn, WO, Fisher, BE, Dowd, KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138 (2010), 315–324.
8. 8 Marco, A, Esteban, JI, Sole, C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol 59 (2013), 45–51.
9. 9 Sherman, KE, Flamm, SL, Afdhal, NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365 (2011), 1014–1024.
10. 10 Cunningham, EB, Applegate, TL, Lloyd, AR, Dore, GJ, Grebely, J, Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. Nat Rev Gastroenterol Hepatol 12 (2015), 218–230.
11. 11 Hill, A, Khoo, S, Fortunak, J, Simmons, B, Ford, N, Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 58 (2014), 928–936.
12. 12 Aspinall, EJ, Corson, S, Doyle, JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 57:suppl 2 (2013), S80–S89.
13. 13 Hellard, M, Scott, N, The changing landscape of hepatitis C treatment—not ‘can we cure?’ but ‘who should we cure first?’ Is this an ethical approach?. Addiction 110 (2015), 984–985.
14. 14 Hellard, M, Rolls, DA, Sacks-Davis, R, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology 60 (2014), 1861–1870.
15. 15 Martin, NK, Vickerman, P, Grebely, J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58 (2013), 1598–1609.
16. 16 Backmund, M, Meyer, K, Edlin, BR, Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 39 (2004), 1540–1543.
17. 17 Bate, JP, Colman, AJ, Frost, PJ, Shaw, DR, Harley, HA, High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J Gastroenterol Hepatol 25 (2010), 1276–1280.
18. 18 Currie, SL, Ryan, JC, Tracy, D, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 93 (2008), 148–154.
19. 19 Dalgard, O, Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 40:suppl 5 (2005), S336–S338.
20. 20 Grady, BP, Vanhommerig, JW, Schinkel, J, et al. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. Eur J Gastroenterol Hepatol 24 (2012), 1302–1307.
21. 21 Grebely, J, Knight, E, Ngai, T, et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 25 (2010), 1281–1284.
22. 22 Grebely, J, Pham, ST, Matthews, GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 55 (2012), 1058–1069.
23. 23 Hilsden, RJ, Macphail, G, Grebely, J, Conway, B, Lee, SS, Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis 57:suppl 2 (2013), S90–S96.
24. 24 Dalgard, O, Bjoro, K, Hellum, K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 8 (2002), 45–49.
25. 25 Aitken, CK, Lewis, J, Tracy, SL, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48 (2008), 1746–1752.
26. 26 Grebely, J, Conway, B, Raffa, JD, Lai, C, Krajden, M, Tyndall, MW, Hepatitis C virus reinfection in injection drug users. Hepatology 44 (2006), 1139–1145.
27. 27 Mehta, SH, Cox, A, Hoover, DR, et al. Protection against persistence of hepatitis C. Lancet 359 (2002), 1478–1483.
28. 28 Micallef, JM, Macdonald, V, Jauncey, M, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 14 (2007), 413–418.
29. 29 Page, K, Hahn, JA, Evans, J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 200 (2009), 1216–1226.
30. 30 van de Laar, TJ, Molenkamp, R, van den Berg, C, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 51 (2009), 667–674.
31. 31 Sacks-Davis, R, Grebely, J, Dore, GJ, et al. Hepatitis C virus reinfection and spontaneous clearance of reinfection—the InC3 study. J Infect Dis 212 (2015), 1407–1419.
32. 32 Midgard, H, Bjoro, B, Maeland, A, et al. Hepatitis C reinfection after sustained virological response. J Hepatol 64 (2016), 1020–1026.
33. 33 Treloar, C, Mao, L, Wilson, H, Beyond equipment distribution in needle and syringe programmes: an exploratory analysis of blood-borne virus risk and other measures of client need. Harm Reduct J, 13, 2016, 1.
34. 34 Pilowsky, DJ, Wu, L-T, Burchett, B, Blazer, DG, Ling, W, Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. Subst Use Misuse 46 (2011), 1716–1725.
35. 35 Hagan, H, Pouget, ER, Des Jarlais, DC, A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 204 (2011), 74–83.
36. 36 Janjua, NZ, Kuo, M, Chong, M, et al. Assessing hepatitis C burden and treatment effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): design and characteristics of linked and unlinked participants. PLoS One, 11, 2016, e0150176.
37. 37 Janjua, NZ, Yu, A, Kuo, M, et al. Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort. BMC Infect Dis, 16, 2016, 334.
38. 38 Janjua, NZ, Kuo, M, Yu, A, et al. The population level cascade of care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine 12 (2016), 189–195.
39. 39 Pampalon, R, Hamel, D, Gamache, P, Philibert, MD, Raymond, G, Simpson, A, An area-based material and social deprivation index for public health in Quebec and Canada. Can J Public Health 103:suppl 2 (2012), S17–S22.
40. 40 Austin, PC, An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46 (2011), 399–424.
41. 41 Harder, VS, Stuart, EA, Anthony, JC, Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods 15 (2010), 234–249.
42. 42 Grady, BP, Schinkel, J, Thomas, XV, Dalgard, O, Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 57:suppl 2 (2013), S105–S110.
43. 43 Ingiliz, P, Martin, TC, Rodger, A, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol, 2016, 10.1016/j.jhep.2016.09.004 published Sept 17.
44. 44 Barua, S, Greenwald, R, Grebely, J, Dore, GJ, Swan, T, Taylor, LE, Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 163 (2015), 215–223.
45. 45 Marshall, AD, Saeed, S, Barrett, L, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 4 (2016), E605–E614.
46. 46 Schaefer, M, Sarkar, R, Diez-Quevedo, C, Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. Clin Infect Dis 57:suppl 2 (2013), S111–S117.
47. 47 Lima, VD, Rozada, I, Grebely, J, et al. Are interferon-free direct-acting antivirals for the treatment of HCV enough to control the epidemic among people who inject drugs?. PLoS One, 10, 2015, e0143836.
48. 48 Golub, ET, Strathdee, SA, Bailey, SL, et al. Distributive syringe sharing among young adult injection drug users in five US cities. Drug Alcohol Depend 91 (2007), S30–S38.
49. 49 Lum, PJ, Sears, C, Guydish, J, Injection risk behavior among women syringe exchangers in San Francisco. Subst Use Misuse 40 (2005), 1681–1696.
50. 50 Kuo, M, Janjua, NZ, Burchell, AN, Buxton, JA, Krajden, M, Gilbert, M, Decreasing hepatitis C incidence among a population with repeated tests: British Columbia, Canada, 1993–2011. Am J Public Health 105 (2015), 1604–1610.
51. 51 Ingiliz, P, Krznaric, I, Stellbrink, HJ, et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 15 (2014), 355–361.
52. 52 Martin, TC, Martin, NK, Hickman, M, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 27 (2013), 2551–2557.
53. 53 Butt Z, Shrestha N, Kuo M, et al. Social disparities and co-evolution of HIV/HCV infections, mental disorders and substance use: the British Columbia Hepatitis Testers Cohort. The 67th annual meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016; November 11–15; Boston, MA, USA, abstr 792.
54. 54 Vickerman, P, Grebely, J, Dore, GJ, et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 205 (2012), 1342–1350.
55. 55 Swain, MG, Lai, MY, Shiffman, ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139 (2010), 1593–1601.
56. 56 Kuo M, Janjua N, Yu A, et al. Assessment of injection drug use based on diagnostic codes in administrative datasets. 25th Annual Canadian Conference on HIV/AIDS Research (CAHR 2016). Winnipeg, Manitoba, Canada 2016, abstr EPHP2.01.
57. 57 Grebely, J, Dore, GJ, Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Res 104 (2014), 62–72.